TITLE

ThromboGenics Extends Runway with $103.2M Raise

AUTHOR(S)
Powers, Marie
PUB. DATE
April 2012
SOURCE
BioWorld International;4/4/2012, Vol. 17 Issue 14, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the 77.8 million euros in funding raised by ThromboGenics NV via a private placement deal with both domestic and international investors. The cash position of Belgium-based ThromboGenics has been boosted to 230 million euros as a result of the deal. ThromboGenics Chief Executive Officer (CEO) Patrik De Haes says the cash increase will enable the firm to commercialize ocriplasmin in the U.S. market.
ACCESSION #
74264540

 

Related Articles

  • ThromboGenics Extends Runway with $103.2M Raise. Powers, Marie // BioWorld Today;3/30/2012, Vol. 23 Issue 62, p1 

    The article reports on the 77.8 million euros in funding raised by ThromboGenics NV via a private placement deal with both domestic and international investors. The cash position of Belgium-based ThromboGenics has been boosted to 230 million euros as a result of the deal. ThromboGenics Chief...

  • Biotech Flourishing in Flanders; Busy Hub a Standout in Europe. Sheridan, Cormac // BioWorld Today;6/3/2013, Vol. 24 Issue 105, p1 

    The article reports on the entry of biotechnology firm Thrombogenics NV into the BEL20 index of Belgium's 20 most heavily traded stocks, which was marked with chief executive officer (CEO) Patrik De Haes ringing the opening bell to begin the proceedings at the 2013 Knowledge for Growth meeting...

  • Financings Roundup.  // BioWorld Today;12/3/2010, Vol. 21 Issue 233, p6 

    The article reports on the launch of a private placement by ThromboGenics NV in Leuven, Belgium.

  • Thrombogenics Files BLA For Ocraplasmin in VMA. Sheridan, Cormac // BioWorld International;12/28/2011, Vol. 16 Issue 52, p1 

    The article focuses on the completion of the biologics license application (BLA) by Leuven, Belgium-based Thrombogenics NV, aside from the acceptance of the European regulators for the review of its ocraplasmin indicated for symptomatic vitreomacular adhesion (VMA). It notes that the decisions...

  • Biotech Flourishing in Flanders; Busy Hub a Standout in Europe. Sheridan, Cormac // BioWorld International;6/5/2013, Vol. 18 Issue 23, p1 

    The article highlights the Knowledge for Growth 2013 meeting held at the International Convention Center in Ghent, Belgium on May 30, 2013. Thrombogenics chief executive officer (CEO) Patrik De Haes announced the entry of the company into the New York Stock Exchange (NYSE) Euronext Brussels...

  • PPL 50.  // Private Placement Letter;6/9/2003, Vol. 21 Issue 23, p5 

    Presents a chart showing the circled traditional private placements as of June 9, 2003.

  • PPL 50.  // Private Placement Letter;8/4/2003, Vol. 21 Issue 31, p6 

    Lists companies which have sought privately placed fixed-income securities financing, as of August 4, 2003.

  • PPL 50.  // Private Placement Letter;10/6/2003, Vol. 21 Issue 38, p6 

    Presents statistics reflecting private placement activities of several corporations as of October 6, 2003.

  • Traditional Private Placement Volume ($ Millions).  // Private Placement Letter;9/19/2005, Vol. 23 Issue 35, p7 

    Presents a chart and graph depicting traditional private placement volume.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics